Section Arrow
Quote
PTHS.NYSE-M
- Pelthos Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/09 07:47 EDT
Pre Market
Last
 --
-- (--)
Bid
9.21
Ask
26.5
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 22.9
+0.16 (+0.70%)
Day High 
26.05 
Prev. Close
22.74 
1-M High
29.25 
Volume 
18.80K 
Bid
9.21
Ask
26.5
Day Low
22.88 
Open
24 
1-M Low
19.975 
Market Cap 
73.58M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 22.02 
20-SMA 22.7 
50-SMA 23.02 
52-W High 54.29 
52-W Low 9 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-23.04/-0.21
Enterprise Value
107.77M
Balance Sheet
Book Value Per Share
11.59
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
16.80M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1831+0.0201+12.33%-- 
Pre Market 0.1676 -0.0155 -8.47%
VRAXVirax Biolabs Group Limited0.15+0.01+7.14%-- 
Pre Market 0.142 -0.008 -5.33%
ELABPmgc Holdings Inc4.5+1.05+30.43%0PE
Pre Market 5.36 +0.86 +19.11%
CUECue Biopharma0.2738+0.0856+45.48%-- 
Pre Market 0.2473 -0.0265 -9.68%
GERNGeron Corp1.71-0.03-1.72%-- 
Pre Market 1.73 +0.02 +1.17%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration(FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities toexpand the NITRICIL nitric oxide-based technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.